Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference
Autonomix Medical (NASDAQ: AMIX) will be featured in two podium presentations at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Conference in San Francisco on October 25-28, 2025.
The presentations on Monday, October 27, highlight positive initial results from the first-in-human proof-of-concept clinical study evaluating the safety and effectiveness of transvascular energy to ablate targeted nerves to mitigate pain in patients with pancreatic cancer. Presenter: Robert S. Schwartz, MD, FACC. Session times: 7:30 AM PDT at Innovation Theater, Hall E (“Illuminating the Nervous System with Transvascular Precision-Guided Technology”), and 9:00 AM PDT at Station 5, Halls B-C (“Pain Mitigation in Pancreatic Adenocarcinoma: An Analysis of Denervation via Transvascular RF Energy-Based Ablation”).
Autonomix Medical (NASDAQ: AMIX) sarà presente in due presentazioni sul podio alla Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Conference a San Francisco dal 25 al 28 ottobre 2025.
Le presentazioni di lunedì 27 ottobre evidenziano i positivi risultati iniziali dal primo studio clinico proof-of-concept nell'uomo che valuta la sicurezza e l'efficacia dell'energia transvascolare per ablare nervi mirati al fine di mitigare il dolore nei pazienti con cancro al pancreas. Presentatore: Robert S. Schwartz, MD, FACC. Orari delle sessioni: 7:30 AM PDT presso Innovation Theater, Hall E (“Illuminating the Nervous System with Transvascular Precision-Guided Technology”), e 9:00 AM PDT presso Station 5, Halls B-C (“Pain Mitigation in Pancreatic Adenocarcinoma: An Analysis of Denervation via Transvascular RF Energy-Based Ablation”).
Autonomix Medical (NASDAQ: AMIX) será presentado en dos ponencias en pódium en la Conferencia Anual Científica Transcatheter Cardiovascular Therapeutics (TCT) en San Francisco del 25 al 28 de octubre de 2025.
Las presentaciones del lunes 27 de octubre destacan resultados iniciales positivos del primer estudio clínico en humanos (proof-of-concept) que evalúa la seguridad y la eficacia de la energía transvascular para ablacionar nervios focalizados con el fin de mitigar el dolor en pacientes con cáncer de páncreas. Presentador: Robert S. Schwartz, MD, FACC. Horarios de las sesiones: 7:30 AM PDT en Innovation Theater, Hall E (“Iluminando el sistema nervioso con tecnología de guía de precisión transvascular”), y 9:00 AM PDT en Station 5, Halls B-C (“Mitigación del dolor en adenocarcinoma pancreático: un análisis de denervación mediante ablación basada en energía RF transvascular”).
Autonomix Medical (NASDAQ: AMIX)는 샌프란시스코에서 2025년 10월 25-28일 열리는 Transcatheter Cardiovascular Therapeutics (TCT) 연례 학술대회에서 두 편의 포디엄 발표로 소개될 예정입니다.
10월 27일 월요일 발표는 췌장암 환자의 통증 완화를 목표로 표적 신경을 제거하기 위해 혈관 경로 에너지를 사용하는 안전성과 효과를 평가하는 최초 인간 대상 개념 증명 임상 연구의 긍정적인 초기 결과를 강조합니다. 발표자: Robert S. Schwartz, MD, FACC. 세션 시간: 7:30 AM PDT 혁신 극장, Hall E(“Transvascular Precision-Guided Technology로 신경계 조명”), 그리고 9:00 AM PDT Station 5, Hall B-C(“Transvascular RF Energy-Based Ablation으로 Denervation 분석에 의한 췌장 선암에서의 통증 완화”).
Autonomix Medical (NASDAQ: AMIX) sera présenté lors de deux allocutions sur scène à la Conférence scientifique annuelle Transcatheter Cardiovascular Therapeutics (TCT) à San Francisco du 25 au 28 octobre 2025.
Les présentations du lundi 27 octobre mettent en évidence des résultats initiaux positifs du premier essai clinique chez l'humain (proof-of-concept) évaluant la sécurité et l'efficacité de l'énergie transvasculaire pour ablater les nerfs ciblés afin d'atténuer la douleur chez les patients atteints d'un cancer du pancréas. Intervenant : Robert S. Schwartz, MD, FACC. Horaires des sessions : 7:30 AM PDT à l’Innovation Theater, Hall E (« Illuminating the Nervous System with Transvascular Precision-Guided Technology »), et 9:00 AM PDT à Station 5, Halls B-C (« Pain Mitigation in Pancreatic Adenocarcinoma: An Analysis of Denervation via Transvascular RF Energy-Based Ablation »).
Autonomix Medical (NASDAQ: AMIX) wird bei zwei Podiumspräsentationen auf der Transcatheter Cardiovascular Therapeutics (TCT) Jahreskonferenz in San Francisco vom 25. bis 28. Oktober 2025 vorgestellt.
Die Präsentationen am Montag, dem 27. Oktober, heben positive erste Ergebnisse aus der ersten-in-human Proof-of-Concept-Studie hervor, die Sicherheit und Wirksamkeit transvascularer Energie zur Ablation gezielter Nerven zur Linderung von Schmerzen bei Patienten mit Bauchspeicheldrüsenkrebs bewertet. Referent: Robert S. Schwartz, MD, FACC. Sitzungszeiten: 7:30 AM PDT im Innovation Theater, Halle E („Illuminating the Nervous System with Transvascular Precision-Guided Technology“), und 9:00 AM PDT Station 5, Hallen B-C („Pain Mitigation in Pancreatic Adenocarcinoma: An Analysis of Denervation via Transvascular RF Energy-Based Ablation“).
Autonomix Medical (NASDAQ: AMIX) ستُعرض في جلستين على المنصة في المؤتمر العلمي السنوي Transcatheter Cardiovascular Therapeutics (TCT) في سان فرانسيسكو من 25 إلى 28 أكتوبر 2025.
تُبرز العروض يوم الاثنين 27 أكتوبر نتائج أولية إيجابية من دراسة إثبات المفهوم الإكلينيكية البشرية الأولى التي تقيم سلامة وفعالية الطاقة عبر الأوعية الدموية لاستئصال الأعصاب المستهدفة لتخفيف الألم لدى مرضى سرطان البنكرياس. المقدم: Robert S. Schwartz, MD, FACC. أوقات الجلسات: 7:30 صباحاً بتوقيت المحيط الهادئ في Innovation Theater، القاعة E (“Illuminating the Nervous System with Transvascular Precision-Guided Technology”)، و9:00 صباحاً بتوقيت المحيط الهادئ في Station 5، القاعات B-C (“Pain Mitigation in Pancreatic Adenocarcinoma: An Analysis of Denervation via Transvascular RF Energy-Based Ablation”).
- None.
- None.
THE WOODLANDS, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will be featured in two podium presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference (TCT 2025) being held October 25-28, 2025 in San Francisco, CA.
The presentations will highlight positive results from the initial phase of Autonomix’s first-in-human proof-of-concept clinical study evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.
Details of the presentations are as follows:
Title: Illuminating the Nervous System with Transvascular Precision-Guided Technology
Session: Innovation Session 7: Percutaneous Denervation for the Treatment of Chronic Diseases
Presenter: Robert S. Schwartz, MD, FACC
Date and Time: Monday, October 27, at 7:30 AM PDT
Location: Innovation Theater, Hall E, Exhibition Level, Moscone North
Title: Pain Mitigation in Pancreatic Adenocarcinoma: An Analysis of Denervation via Transvascular RF Energy-Based Ablation
Session: Hypertension and Renal (and other organ system) Denervation - 2
Presenter: Robert S. Schwartz, MD, FACC
Date and Time: Monday, October 27, at 9:00 AM PDT
Location: Station 5, Halls B-C, Exhibition Level, Moscone South
For more information about TCT 2025, visit the conference website here.
About TCT 2025
TCT 2025 is a comprehensive 4-day educational conference, sponsored by the Cardiovascular Research Foundation (CRF), taking place October 25-28, 2025, at the Moscone Center in San Francisco, California. Founded by Dr. Martin B. Leon, the Transcatheter Cardiovascular Therapeutics® (TCT®) conference is the annual scientific symposium of the Cardiovascular Research Foundation® (CRF®) and the world’s foremost educational forum specializing in interventional cardiovascular medicine. Debuting as a small gathering of 150 in 1988, TCT® now attracts thousands of attendees from around the world. Every year, TCT® features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What will Autonomix (AMIX) present at TCT 2025 on October 27, 2025?
When and where is the Autonomix (AMIX) presentation titled "Illuminating the Nervous System with Transvascular Precision-Guided Technology"?
What is the focus of Autonomix's (AMIX) 9:00 AM PDT presentation at TCT 2025?
Who is the presenter for Autonomix's (AMIX) podium sessions at TCT 2025?
Does Autonomix (AMIX) report clinical results at TCT 2025?
